Have a feature idea you'd love to see implemented?
Let us know!
NVCR NovoCure Ltd
Price (delayed)
$17.09
Market cap
$1.85B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.39
Enterprise value
$2.34B
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating
Highlights
NVCR's EPS is up by 25% year-on-year and by 11% since the previous quarter
The net income has grown by 24% YoY and by 11% from the previous quarter
The company's quick ratio has shrunk by 78% YoY and by 77% QoQ
NovoCure's debt has increased by 15% YoY
Key stats
What are the main financial stats of NVCR
Market
Valuations
Earnings
Shares outstanding
108.2M
Market cap
$1.85B
Enterprise value
$2.34B
Price to book (P/B)
5.13
Price to sales (P/S)
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.04
Revenue
$577.74M
EBIT
-$158.91M
EBITDA
-$148.05M
Free cash flow
-$78.21M
Per share
Balance sheet
Liquidity
EPS
-$1.39
Free cash flow per share
-$0.72
Book value per share
$3.33
Revenue per share
$5.34
TBVPS
$11.29
Total assets
$1.22B
Total liabilities
$861.21M
Debt
$675.63M
Equity
$360.78M
Working capital
$360.27M
Debt to equity
1.87
Current ratio
1.49
Quick ratio
1.44
Net debt/EBITDA
-3.29
Margins
Efficiency
Dividend
EBITDA margin
-25.6%
Gross margin
76.4%
Net margin
-25.9%
Operating margin
-27.5%
Return on assets
-12.7%
Return on equity
-41.5%
Return on invested capital
-12.9%
Return on capital employed
-32.6%
Return on sales
-27.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NVCR stock price
How has the NovoCure stock price performed over time
Intraday
1.36%
1 week
3.14%
1 month
5.04%
1 year
39.74%
YTD
14.47%
QTD
9.34%
Financial performance
How have NovoCure's revenue and profit performed over time
Revenue
$577.74M
Gross profit
$441.47M
Operating income
-$158.91M
Net income
-$149.78M
Gross margin
76.4%
Net margin
-25.9%
NovoCure's operating margin has increased by 38% YoY and by 18% QoQ
NovoCure's net margin has increased by 34% YoY and by 16% from the previous quarter
NovoCure's operating income has increased by 29% YoY and by 14% QoQ
The net income has grown by 24% YoY and by 11% from the previous quarter
Growth
What is NovoCure's growth rate over time
Valuation
What is NovoCure stock price valuation
P/E
N/A
P/B
5.13
P/S
3.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.04
NVCR's EPS is up by 25% year-on-year and by 11% since the previous quarter
The price to book (P/B) is 76% lower than the 5-year quarterly average of 21.2 but 9% higher than the last 4 quarters average of 4.7
The equity has declined by 8% year-on-year
NVCR's price to sales (P/S) is 80% lower than its 5-year quarterly average of 15.8 but 3.2% higher than its last 4 quarters average of 3.1
The company's revenue rose by 15% YoY and by 5% QoQ
Efficiency
How efficient is NovoCure business performance
NVCR's return on sales is up by 38% year-on-year and by 18% since the previous quarter
The company's return on assets rose by 25% YoY and by 13% QoQ
NovoCure's ROIC has increased by 17% YoY and by 6% from the previous quarter
NovoCure's return on equity has increased by 12% YoY and by 9% QoQ
Dividends
What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NVCR.
Financial health
How did NovoCure financials performed over time
NovoCure's total assets is 42% more than its total liabilities
The company's quick ratio has shrunk by 78% YoY and by 77% QoQ
The company's current ratio has shrunk by 78% YoY and by 77% QoQ
NovoCure's debt is 87% more than its equity
NVCR's debt to equity is up by 25% YoY
NovoCure's debt has increased by 15% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.